High patient compliance with nicacin/laropiprant in large clinical trial Interim safety and tolerability results from HPS-2 THRIVE study released at 2012 ESC congress

被引：0

作者：

不详

机构：

来源：

CARDIOVASCULAR JOURNAL OF AFRICA | 2012年 / 23卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Of the patients randomised to niacin/laropiprant in the HPS-2 THRIVE study, 75% remained compliant after three years of therapy with the combination of an extended-release niacin and the non-flushing agent, laropiprant. HPS-2 THRIVE is a heart-protection study focused on treating high-density lipoprotein (HDL) cholesterol to reduce the incidence of vascular events.

引用

页码：471 / 471

页数：1